Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

(2024-11-07 | NYSE:JNJ) Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024. Stockhouse.com uses cookies on this site. By continuing to use our service, ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral ...